These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 11858873

  • 1. Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries.
    Amersdorfer P, Wong C, Smith T, Chen S, Deshpande S, Sheridan R, Marks JD.
    Vaccine; 2002 Feb 22; 20(11-12):1640-8. PubMed ID: 11858873
    [Abstract] [Full Text] [Related]

  • 2. Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries.
    Amersdorfer P, Wong C, Chen S, Smith T, Deshpande S, Sheridan R, Finnern R, Marks JD.
    Infect Immun; 1997 Sep 22; 65(9):3743-52. PubMed ID: 9284147
    [Abstract] [Full Text] [Related]

  • 3. Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display.
    Levy R, Forsyth CM, LaPorte SL, Geren IN, Smith LA, Marks JD.
    J Mol Biol; 2007 Jan 05; 365(1):196-210. PubMed ID: 17059824
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Characterization of neutralizing antibodies and identification of neutralizing epitope mimics on the Clostridium botulinum neurotoxin type A.
    Wu HC, Yeh CT, Huang YL, Tarn LJ, Lung CC.
    Appl Environ Microbiol; 2001 Jul 05; 67(7):3201-7. PubMed ID: 11425742
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity.
    Khouri JM, Motter RN, Arnon SS.
    Vaccine; 2018 Apr 05; 36(15):2041-2048. PubMed ID: 29475762
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Immunological characterisation and immunoprotective efficacy of functional domain antigens of botulinum neurotoxin serotype A.
    Liu FJ, Shi DY, Mao YY, Xiong XH, Lu JS, Pang XB, Dong XJ, Yang ZX, Yu YZ.
    Vaccine; 2020 Mar 23; 38(14):2978-2983. PubMed ID: 32113807
    [Abstract] [Full Text] [Related]

  • 16. Synergistic capture of Clostridium botulinum type A neurotoxin by scFv antibodies to novel epitopes.
    Gray SA, Barr JR, Kalb SR, Marks JD, Baird CL, Cangelosi GA, Miller KD, Feldhaus MJ.
    Biotechnol Bioeng; 2011 Oct 23; 108(10):2456-67. PubMed ID: 21538339
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Localization of the regions on the C-terminal domain of the heavy chain of botulinum A recognized by T lymphocytes and by antibodies after immunization of mice with pentavalent toxoid.
    Rosenberg JS, Middlebrook JL, Atassi MZ.
    Immunol Invest; 1997 Jun 23; 26(4):491-504. PubMed ID: 9246568
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.